103. Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study

Controlled Trial ◽

Certolizumab Pegol ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Randomized Controlled ◽

FRI0186 Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.1313 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A435.1-A435 ◽

Cited By ~ 3

Author(s):

R. Fleischmann ◽

R. van Vollenhoven ◽

J. Vencovsky ◽

R. Alten ◽

O. Davies ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Combination Therapy ◽

Certolizumab Pegol ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial

American Journal of Respiratory and Critical Care Medicine ◽

10.1164/rccm.202103-0714oc ◽

2021 ◽

Author(s):

Dinesh Khanna ◽

Celia J. F. Lin ◽

Daniel E Furst ◽

Bridget Wagner ◽

Mauro Zucchetto ◽

...

Keyword(s):

Systemic Sclerosis ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Safety And Efficacy ◽

Randomized Controlled ◽

Open Label Extension ◽

Early Systemic Sclerosis

Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial

Epilepsy Research ◽

10.1016/j.eplepsyres.2021.106705 ◽

2021 ◽

pp. 106705

Author(s):

Yushi Inoue ◽

Weiping Liao ◽

Xuefeng Wang ◽

Xinlu Du ◽

Frank Tennigkeit ◽

...

Keyword(s):

Controlled Trial ◽

Open Label ◽

Safety And Efficacy ◽

Randomized Controlled ◽

Focal Seizures ◽

Japanese Adults ◽

Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients with Dementia with Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial

American Journal of Geriatric Psychiatry ◽

10.1016/j.jagp.2021.07.002 ◽

2021 ◽

Author(s):

Toshinari Odawara ◽

Kazuko Hasegawa ◽

Ritsuko Kajiwara ◽

Hisao Takeuchi ◽

Masaaki Tagawa ◽

...

Keyword(s):

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

THU0192 5-Year Results from the Rapid 1 Trial and Open-Label Extension: Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.720 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A228.2-A229 ◽

Cited By ~ 4

Author(s):

E. Keystone ◽

R. Landewé ◽

R. van Vollenhoven ◽

B. Combe ◽

V. Strand ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Certolizumab Pegol ◽

Open Label ◽

Safety And Efficacy ◽

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)70394-0 ◽

2007 ◽

Vol 2007 ◽

pp. 101-102

Author(s):

B.H. Thiers

Keyword(s):

Clinical Response ◽

Controlled Trial ◽

Severe Psoriasis ◽

Extension Study ◽

Open Label ◽

Double Blind ◽

Randomized Controlled ◽

Open Label Extension ◽

Adalimumab Treatment

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2006.05.027 ◽

2006 ◽

Vol 55 (4) ◽

pp. 598-606 ◽

Cited By ~ 322

Author(s):

Kenneth B. Gordon ◽

Richard G. Langley ◽

Craig Leonardi ◽

Darryl Toth ◽

M. Alan Menter ◽

...

Keyword(s):

Clinical Response ◽

Controlled Trial ◽

Severe Psoriasis ◽

Extension Study ◽

Open Label ◽

Double Blind ◽

Randomized Controlled ◽

Open Label Extension ◽

Adalimumab Treatment

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Arthritis Research & Therapy ◽

10.1186/s13075-019-1857-3 ◽

2019 ◽

Vol 21 (1) ◽

Cited By ~ 9

Author(s):

Stanley Cohen ◽

Jose L. Pablos ◽

Karel Pavelka ◽

Gerard Anton Müller ◽

Alan Matsumoto ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Open Label Extension ◽

Abp 501

Efficacy of long-term (104-week) treatment with apremilast in patients with psoriatic arthritis: Results from a phase III, randomized, controlled trial and open-label extension

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.968 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB248

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase Iii ◽

Open Label ◽

Randomized Controlled ◽

PMS67 Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy on Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study

Value in Health ◽

10.1016/j.jval.2012.08.1422 ◽

2012 ◽

Vol 15 (7) ◽

pp. A451-A452

Author(s):

V. Strand ◽

O. Purcaru ◽

R. Van vollenhoven ◽

E. Choy ◽

R. Fleischmann

Keyword(s):

Rheumatoid Arthritis ◽

Social Participation ◽

Certolizumab Pegol ◽

Extension Study ◽

Open Label ◽

Open Label Extension ◽

Household Productivity